New Delhi – India's central government has significantly expanded its drug licensing framework, bringing advanced cell and gene therapies under stringent regulatory oversight. An amendment to the Drugs Rules, 1945, now includes stem cell-derived products, gene therapeutic products, and xenografts within the purview of the Centrally Licence Approving Authority (CLAA).
This move is designed to establish uniform regulatory standards and enhance scrutiny over emerging medical technologies. Previously, the CLAA framework primarily covered critical drugs and biological products such as vaccines, large-volume parenterals, and recombinant DNA-based medicines.
Enhanced Scrutiny for Complex Therapies
The Ministry of Health and Family Welfare highlighted the specific categories now subject to the updated regulations:
- Cell or Stem Cell-Derived Products: This includes regenerative treatments and cutting-edge CAR-T cell therapies, which are increasingly vital in treating blood cancers like leukaemias and lymphomas.
- Gene Therapeutic Products: Encompassing gene replacement and gene-editing therapies, these are crucial for addressing genetic disorders and various forms of cancer.
- Xenografts: Products derived from animal tissues, such as heart valves transplanted into humans, commonly used in cardiology and orthopaedics.
The government emphasized that these technologies represent highly complex, specialized, and rapidly evolving areas of medical science, necessitating enhanced regulatory scrutiny to ensure patient safety. The inclusion under the CLAA framework facilitates joint oversight by both Central and State Licensing Authorities, promoting greater uniformity in regulatory standards nationwide.
Safeguarding Public Health and Fostering Innovation
For patients, the amendment is expected to bolster regulatory oversight without immediately altering access to existing treatments. The primary objective is to ensure that therapies like CAR-T cells, gene therapies, and stem cell-derived treatments undergo rigorous evaluation under consistent standards before becoming available to the public.
Officials stated that this amendment strengthens the regulatory rigour for emerging technologies and aligns India's regulatory framework with global best practices and scientific advancements. It underscores the government's commitment to safeguarding public health while simultaneously promoting innovation and facilitating the adoption of newer technologies within the healthcare and life sciences sectors.